" class="no-js "lang="en-US"> Erik Gatenholm Archives - Medtech Alert
Saturday, September 30, 2023

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

BICO Group Adds Senior Ir Manager to Its Executive Management

Åsa Hillsten has been appointed SVP and Head of IR at BICO and will be […]

BICO Partners with the Center for Contemporary Sciences (CCS) to Reduce Animal Testing in Life Sciences

Today BICO, a leading bio convergence company, announced a partnership with the Center for Contemporary […]

BICO and Nanochon Announce Commercial Agreement to Develop 3D Printed Joint Restoration Implant

Today BICO, the world’s leading bio convergence company, announced partnership with Nanochon, a startup developing regenerative joint replacements. Under […]

BICO’s CYTENA Signs USD 10 Million Deal to Distribute Single Cell Isolators in China to Accelerate Development of Next Generation Therapies

Today CYTENA, a BICO company, announced it has signed a 2-year deal with Applitech Pharmaceutical Equipment Technology to […]

BICO Announces Appointment of Susan Tousi as New Member of the Board of Directors

Today BICO, the world’s leading Bio Convergence company announced it has added Susan Tousi to […]

BICO Strengthens IP Portfolio with Patents in the United States and Sweden for 3D Bioprinting of Temperature Sensitive Bioinks

BICO, the world’s leading bio convergence company, has been granted two patents relating to the […]

Bico has Acquired Advanced Biomatrix, an Innovative Company Focused on 3d Applications, to, Together, Ensure a Market Leading Portfolio of Bioinks and Reagents

BICO, the leading Bio Convergence company, has acquired all outstanding shares in Advanced BioMatrix Corp. […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more